BAY 43-9006 also targets the vascular endothelial growth factor (VEGF) receptors, VEGFR-2 and VEGFR-3, and platelet-derived growth factor receptor-β (PDGFR-β) – key RTKs involved in tumour progression and angiogenesis (Wilhelm et al, 2004). This evidence concerns the gene VEGFA and neoplasm.